ProQR Therapeutics Ratios (2021-2025) | PRQR

Ratios Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
EBT Margin -8,583.69%-5,433.33%-1,669.38%-7,250.21%-1,508.32%-1,702.37%-2,435.26%-1,730.56%-1,433.44%-731.20%-539.49%-190.86%-181.46%-57.10%-226.80%-234.06%-239.34%-320.91%-391.53%
EBIT Margin -8,583.69%-5,433.33%-1,669.38%-7,250.21%-1,508.32%-1,702.37%-2,435.26%-1,730.56%-1,433.44%-731.20%-539.49%-190.86%-181.46%-57.10%-226.80%-234.06%-239.34%-320.91%-391.53%
EBITDA Margin 8,668.09%6,540.74%1,704.47%-7,565.69%1,229.65%1,375.70%2,787.71%-1,626.67%1,385.34%-661.41%-420.07%-190.86%167.80%41.35%220.79%-234.06%231.25%336.94%382.69%
Operating Margin -8,583.69%-5,433.33%-1,669.38%-7,250.21%-1,508.32%-1,702.37%-2,435.26%-1,730.56%-1,433.44%-731.20%-539.49%-190.86%-181.46%-57.10%-226.80%-234.06%-239.34%-320.91%-391.53%
Net Margin -8,941.13%-6,537.86%-1,725.57%-7,623.85%-1,248.58%-1,473.12%-2,864.62%-1,846.81%-1,397.25%-663.32%-441.24%-150.30%-172.09%-42.70%-220.79%-213.70%-231.25%-336.94%-382.69%
FCF Margin -8,318.44%-4,085.19%-903.90%1,677.82%-1,789.65%-1,571.29%-1,857.25%-2,675.28%
Efficiency
Assets Average 55.35B0.21B0.24B0.23B0.20B0.16B0.15B0.17B0.17B0.16B0.15B
Invested Capital 0.00B0.02B0.02B0.18B0.04B0.04B0.00B0.08B0.00B0.00B0.00B0.06B0.11B
Asset Utilization Ratio 0.010.010.020.020.030.020.020.030.05
Leverage & Solvency
Debt to Equity 0.390.100.100.05
Debt Ratio 0.000.100.090.210.200.210.040.040.020.020.020.030.03
Equity Ratio 0.540.390.300.53
Valuation
Enterprise Value -0.09B-0.09B-0.17B-0.22B-0.19B-0.20B-0.19B-0.10B-0.15B-0.14B-0.13B-0.13B-0.16B
Return Ratios
Return on Sales -85.84%-54.33%-16.69%-72.50%-15.08%-17.02%-24.35%-17.31%-14.33%-7.31%-5.39%-1.91%-1.81%-0.57%-2.27%-2.34%-2.39%-3.21%-3.92%
Return on Capital Employed -0.33%-0.36%-0.42%-0.58%-0.54%-0.39%-0.37%-0.31%-0.30%
Return on Assets -0.29%-0.32%-0.36%-0.48%-0.46%-0.35%-0.32%-0.26%-0.23%